anti-SET Domain Containing (Lysine Methyltransferase) 7 (SETD7) Antibodies

Human SET Domain Containing (Lysine Methyltransferase) 7 (SETD7) interaction partners

1. Methylation at K436 and K595 respectively by Set7 increases the stability and DNA binding ability of Gli3 (show GLI3 Antibodies), resulting in an enhancement of Shh (show SHH Antibodies) signaling activation.

2. the methyltransferase Set9 potentiates TGF-beta (show TGFB1 Antibodies) signaling by targeting Smad7 (show SMAD7 Antibodies), an inhibitory downstream effector.

3. SETD7 plays a critical role in HCC (show FAM126A Antibodies), and its immunohistochemistry signature provides potential clinical significance for personalized prediction of HCC (show FAM126A Antibodies) prognosis.

4. These findings underscore the role of KMT7 as an important monomethyltransferase regulating HIV transcription through Tat (show TAT Antibodies).

5. High SET7 expression is associated with breast cancer.

6. SET7 was required for GATA1 (show GATA1 Antibodies)-induced breast tumor angiogenesis and growth in nude mice. GATA1 (show GATA1 Antibodies) and SET7 are independent poor prognostic factors in breast cancer.

7. SET7/SET9-mediated YY1 (show YY1 Antibodies) methylation was shown to be involved in YY1 (show YY1 Antibodies)-regulated gene transcription and cell proliferation.

8. These results demonstrate that S...O chalcogen bonds contribute to AdoMet (show MAT1A Antibodies) recognition and can enable methyltransferases to distinguish between substrate and product.

9. Reduced expression of SET7 is associated with gastric cancer progression.

10. study identified a novel locus associated with serum lycopene concentrations and results raise a number of possibilities regarding the nature of the relationship between SETD7 and lycopene, both independently associated with prostate cancer.

Mouse (Murine) SET Domain Containing (Lysine Methyltransferase) 7 (SETD7) interaction partners

1. the methyltransferase Set9 potentiates TGF-beta (show TGFB1 Antibodies) signaling by targeting Smad7 (show SMAD7 Antibodies), an inhibitory downstream effector.

2. SETD7 plays an important role in intestinal epithelial cell (IEC) biology during infection.

3. We observe Set7-mediated modification of serum response factor (SRF) and mono-methylation of histone H4 lysine 4 (H3K4me1) regulate gene expression. We conclude the broad substrate specificity of Set7 serves to control key transcriptional networks in embryonic stem cells.

4. SETD7 is required for Wnt (show WNT2 Antibodies)-driven intestinal tumorigenesis and regeneration. SETD7-dependent methylation of YAP (show YAP1 Antibodies) facilitates Wnt (show WNT2 Antibodies)-induced nuclear accumulation of beta-catenin (show CTNNB1 Antibodies).

5. SET7/9 regulates Nos2 expression through methylation of H3K4 in beta cells.

6. Data indicate that the ability of transcription factor Pdx1 (show PDX1 Antibodies) to regulate genes in beta cells is partially dependent upon its methylation by methyltransferase Set7/9.

7. study found that Set7 is a modifier of the Hippo pathway. Mice that lack Set7 have a larger progenitor compartment in the intestine, coinciding with increased expression of Yes-associated protein target genes.

8. The response to hyperglycemia in vascular endothelial cells involves Set7 mediated changes in chromatin remodeling and gene expression.

9. Set7/9-mediated methylation of p53 (show TP53 Antibodies) does not represent a major regulatory event and does not appreciably control p53 (show TP53 Antibodies) activity in vivo.

10. Set7/9 is dispensable for p53 (show TP53 Antibodies) function in the mouse.